Market Overview on Aurora Kinase ASerine/Threonine-Protein Kinase 15-Pipeline Review, H1 2016

Aurora Kinase ASerine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Aurora Kinase ASerine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report assesses Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 

- The report summarizes all the dormant and discontinued pipeline projects 

- The report reviews latest news and deals related to Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AbbVie Inc. Amgen Inc. Astex Pharmaceuticals, Inc. CASI Pharmaceuticals Inc. Merck & Co., Inc. Millennium Pharmaceuticals, Inc. Sanofi Sareum Holdings Plc Sigma-Tau S.p.A. Taiho Pharmaceutical Co., Ltd. Vertex Pharmaceuticals Incorporated Vichem Chemie Research Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###